Answer:
99% water, sodium chloride, trace amounts of wastes, and vitamin C
Explanation:
Eccrine glands are the main and major sweat glands of our body. These glands are found all over the skin but their density is higher on palm, soles, and head.
99% of the secretion of the eccrine gland is water and in rest 1% it contains sodium, trace amounts of waste and a high amount of vitamin C is lost by the eccrine gland.
As the eccrine gland is responsible for sweating so it helps in thermoregulation in the body. As 99% of secretion is water therefore dehydration and water loss is the major worry during excessive sweating.
Answer:
If predominantly, we can't say of any treatment for progeria, aside from the routine observation of heart and blood vessel (cardiovascular) disease which is important in taking care of the health situation in the affected kids. Treatment relies majorly on the situation and clinical manifestations of the kid. At first, in 1999, the findings of the initial clinical drug trial for kids with an unusual rapid-aging disease, often referred to as Progeria, revealed positive results with a farnesyltransferase inhibitor (FTI), a drug initially designed to treat cancer.
The PATHWAY in gene expression to be TARGETED is progenin formulation---
The Progeria-forming mutation results in the formation of the protein progerin that disrupts the cell activities. Some areas of progerin's toxic impact on the body is due to the formation of a farnesyl group, Â that adheres to the progerin protein aiding it's disruption of the body's cells. FTIs means of action is through inhibition of the adhesion of the farnesyl group to progerin, decreasing the hazardous substances that leads to progerin.
The genetic medicine technique that acts as.an intervention tool gene therapy to regulate the gene that causes the stimulation and formation of the protein progenin.
Escalated cardiovascular disease results in death in the case of Progeria.
It's worthwhile to note that if the basic blood vessels can with time get better as a result of treatment, the treatment shows positive results. Slowing down stroke and aging manifestations will boost the chances of treatment.
Answer: C. Shadow length decreased from sunrise to noon.
Explanation: Think about how the sun is positioned in the sky. If it was noon, the sun is above the stick which means little to no shadow at all. If the sun was rising, its hitting one side of the stick, making the shadow longer.
A) yellow, smooth
Just substitute the yellow/green peas for yellow/green leaves
The answers are as follows:
1. <span>An inhibitor has a structure that is so similar to the substrate that it can bond to the enzyme just like the substrate: t</span>his is called competitive inhibitor. A competitive inhibitor will compete with the substrate for the active site of the enzyme and bind to the active site, thus incapacitating the substrate from binding to the active site.
2. An inhibitor binds to a site on the enzyme that is not the active site: this is called non competitive inhibitors. Non competitive inhibitors bind to other site in the enzyme which is not the active site of the enzyme. The binding of the inhibitor changes the conformation of the enzyme as well as the active site, thus making it impossible for the substrate to bind to the enzyme effectively.
3. <span>usually, a(n) inhibitor forms a covalent bond with an amino acid side group within the active site, which prevents the substrate from entering the active site or prevents catalytic activity: this is called irreversible or permanent inhibition. Permanent inhibitors form covalent bonds with the enzyme and prevent substrate from binding to the enzyme.
4. T</span><span>he competitive inhibitor competes with the substrate for the ACTIVE SITE on the enzyme: The active site of an enzyme is the place where the substrate normally bind in order to activate a enzyme. Competitive inhibitors are those inhibitors that compete with the substrate for the active site of the enzyme and prevent the substrate from binding there.
5. W</span><span>hen the noncompetitive inhibitor is bonded to the enzyme, the shape of the ENZYME is distorted. The non competitive inhibitors are those inhibitors that bind to other places in the enzyme instead of the active site. The binding of the non competitive inhibitor usually distort the shape and the conformation of the enzyme thus preventing the substrate from binding to it effectively.
6. E</span><span>nzyme inhibitors disrupt normal interactions between an enzyme and its SUBSTRATE. The principal function of enzyme inhibitor is to prevent the substrate from binding to the appropriate enzyme. This is usually done in the human system in order to regulate the activities of enzymes.</span>
